AtriCure Inc (Nasdaq:ATRC) on Tuesday reported the completion of the acquisition of SentreHEART Inc for an undisclosed amount.
Based in Redwood City, California, SentreHEART is a privately-owned medical device company committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-centre, randomized controlled trial (aMAZE Trial).
Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage (LAA).
According to AtriCure Inc, it provides innovative technologies for the treatment of Afib and related conditions. The electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.
DisposeRx Inc awarded first US patent for at-home medication disposal packets
ANI Pharmaceuticals wins FDA approval of Potassium Citrate Extended-Release Tablets USP
Cellectis doses first AML patient with new allogeneic UCART123 product candidate
Revenio Group's Icare ic200 intraocular pressure measurement device approved by US FDA
BioProtect reports USD13m from initial closing of Series D equity financing
Phagenesis wins FDA breakthrough device designation for Phagenyx System to treat dysphagia
Bigfoot Biomedical raises USD45m in the initial tranche of Series C equity financing led by Abbott
Ascelia Pharma opens up five more sites for patient enrolment under phase III clinical study SPARKLE